The Current State of Human Research on BPC-157: Ulcerative Colitis, Interstitial Cystitis, and Multiple Sclerosis
Key Points
Almost all information about BPC-157 comes from animal experiments.
Human studies are few and small.
Some studies showed some potential but ultimately yielded little.
As BPC-157 use grows in the population, new research is urgently needed.
1. Why Human Evidence Is So Scarce
Before going further, it is necessary to state clearly how scarce human evidence on BPC-157 currently is.
Almost all information about BPC-157 comes from animal experiments. Human studies are few and small.
Below are some of the more notable studies.
2. Ulcerative Colitis: Early Croatian Trials
Early human trials in patients with ulcerative colitis are among the few gastrointestinal studies on BPC-157.
Multiple reviews have cited early Croatian clinical trials in patients with inflammatory bowel disease.
The peptide was reportedly used to treat mild to moderate ulcerative colitis, with no major safety issues reported.
However, the full dataset was never fully published, making independent evaluation difficult.
3. Interstitial Cystitis: A Small 12-Person Pilot Trial
A small pilot trial in 12 patients with interstitial cystitis (a painful bladder condition) showed that after a single bladder injection, 10 of the 12 patients reported complete resolution of symptoms, and the remaining 2 reported about 80% improvement.
No adverse reactions were reported.
4. Safety Check in Healthy Adults
A safety check was conducted in only two healthy adults, with intravenous doses up to 20 mg.
No adverse reactions occurred, blood test results were normal, and the drug was cleared from the blood within 24 hours.
5. Multiple Sclerosis and Phase I Safety Trials
Some clinical trials were conducted for multiple sclerosis, but a lethal dose was never found.
In 2015, a Phase I safety trial in 42 healthy volunteers began, but the results were never published.
6. Why These Studies Are Insufficient to Support Firm Conclusions
These studies are all small, and some lack proper controls.
The problem is that all of these studies showed some potential but ultimately yielded little.
As BPC-157 use grows in the population, new research is urgently needed.
7. Summary
The current state of human research on BPC-157 can be summarized as follows:
First, ulcerative colitis: early Croatian trials, full data not published.
Second, interstitial cystitis: a small 12-person pilot, 10 reported complete symptom resolution.
Third, healthy adults: only 2 people, 20 mg intravenous, no adverse reactions.
Fourth, multiple sclerosis: some trials, no lethal dose found.
Fifth, Phase I safety trial: 42 healthy volunteers, results never published.
These studies are small and some lack controls, so they cannot be regarded as clinical fact.
Frequently Asked Questions
Are there human clinical trials on BPC-157?
Yes, but they are few and small. Some results were never fully published.
What were the results of the ulcerative colitis trial?
The peptide was reportedly used to treat mild to moderate ulcerative colitis, with no major safety issues reported. But the full dataset was never fully published, making independent evaluation difficult.
What were the results of the interstitial cystitis trial?
Of 12 patients, 10 reported complete resolution of symptoms, and the remaining 2 reported about 80% improvement. No adverse reactions were reported.
Why is human evidence for BPC-157 still insufficient?
Because existing studies are small, some lack controls, and some results were never published. More large-scale, strictly controlled human trials are needed.